$NBIO has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab ("PTB"
as a treatment for Primary and Metastatic Brain Cancers.
Sean Carrick, Nascent CEO, explains, "We are enthusiastically encouraging anyone interested in screening for the trial to do so in a timely manner. This cohort of patients will likely be the final one in this trial, and new patient enrollment will cease until our Phase II research gets underway."
as a treatment for Primary and Metastatic Brain Cancers. Sean Carrick, Nascent CEO, explains, "We are enthusiastically encouraging anyone interested in screening for the trial to do so in a timely manner. This cohort of patients will likely be the final one in this trial, and new patient enrollment will cease until our Phase II research gets underway."